Nifedipine: Difference between revisions
| Line 25: | Line 25: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*CHF | |||
*pulmonary edema | |||
*MI | |||
*arrhythmias | |||
*hypotension, severe | |||
*cholestasis | |||
*allergic hepatitis | |||
*angioedema | |||
*anaphylaxis | |||
*Stevens-Johnson syndrome | |||
*exfoliative dermatitis | |||
*toxic epidermal necrolysis | |||
*exanthematous pustulosis, acute generalized | |||
*GI obstruction (XL form) | |||
*GI ulcer (XL form) | |||
===Common=== | ===Common=== | ||
Revision as of 22:55, 26 June 2015
General
- Type: Calcium Channel Blocker, Dihydropyridine
- Dosage Forms: PO
- Common Trade Names: Procardia, Nifediac, Nifedical, Adalat, Afeditab
Adult Dosing
Preterm labor/Tocolysis
- 20mg x1, additional 20mg dose in 90min if ctx persist, followed by 20mg q3-8 hrs prn ctx
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- CHF
- pulmonary edema
- MI
- arrhythmias
- hypotension, severe
- cholestasis
- allergic hepatitis
- angioedema
- anaphylaxis
- Stevens-Johnson syndrome
- exfoliative dermatitis
- toxic epidermal necrolysis
- exanthematous pustulosis, acute generalized
- GI obstruction (XL form)
- GI ulcer (XL form)
Common
Pharmacology
- Half-life: 2h, 7h (ER)
- Metabolism: liver, CYP450: 3A4 substrate
- Excretion: urine 60-80% (<0.1% unchanged), bile/feces 20%
- Mechanism of Action: inhibits calcium ion influx into vascular smooth muscle and myocardium